First-ever mRNA multi-cancer panel simultaneously screens for multiple cancers from a single sample of blood
TORONTO, ON and RICHMOND, VA / ACCESSWIRE / November 22, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that people throughout the Greater Toronto Area can now access the company's multi-cancer blood test ARISTOTLE®. Built on StageZero's proprietary mRNA technology, ARISTOTLE® is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood.
Cancer is the leading cause of death in Canada.1 In 2021, an estimated 229,000 Canadians will be diagnosed with cancer.1 Treatment is most likely to be effective when cancer is diagnosed at an early stage; however, some of the most common cancers are not diagnosed until symptoms arise and the tumor has progressed to an advanced stage.1 For example, currently about 50% of colorectal cancers are diagnosed at stage III or IV.1
"Far too often, cancer is diagnosed and treated at a late stage, which can dramatically decrease survival rates and affect patients' quality of life," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "This is more of an issue now, with the COVID-19 pandemic having significantly reduced patient/physician interactions. We are seeing a wave of late-stage diagnoses" he continued. "Use of a blood test that looks for the most common forms of treatable cancers can help reduce the risk of developing advanced-stage cancer through early detection. We believe that providing an opportunity to find cancer early will facilitate more favorable outcomes."
ARISTOTLE® must be prescribed by a physician and is available through AVRT™, the Company's comprehensive telehealth program which uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages. Through AVRT™, patients who have a molecular signature for cancer detected via ARISTOTLE® are paired with a dedicated case manager, oncologist, and/or other healthcare professionals to guide them on next steps.
Collaborations with clinics in the Greater Toronto Area will facilitate specimen collection and are part of StageZero's physical hub-and-spoke model which is being deployed as part of the Company's long-term Global Growth Strategy.
ARISTOTLE® is the first-ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The ARISTOTLE® test works by interrogating mRNA from a sample of whole blood and detecting gene expression profiles indicative of specific cancers. ARISTOTLE® screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.
To learn more, please visit https://www.stagezerolifesciences.com/aristotle-test.html.
# # #
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Important Safety Information
The Aristotle®, ColonSentry®, and BreastSentry™ tests were developed, and their performance characteristics determined, by Stage Zero Life Sciences, Inc. They have not been cleared or approved by the U.S. Food and Drug Administration. These tests are performed in a CLIA certified laboratory and are intended for clinical purposes. These tests must be ordered by and used only in consultation with a healthcare provider.
For further information please contact:
1-855-420-7140 ext. 1838
SOURCE: StageZero Life Sciences Ltd